View in EDS HTML Full Text PDF Full Text

Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.

Saved in:
Bibliographic Details
Title: Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.
Authors: Machiels JP; Department of Medical Oncology, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique (Pole MIRO), UCLouvain, Brussels, Belgium., Tao Y; Department of Radiation Oncology, Gustave Roussy, Villejuif, France., Licitra L; Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy., Burtness B; Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States., Tahara M; Division of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Rischin D; Medical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, VIC, Australia., Alves GV; Medical Oncology, Centro Integrado de Pesquisa em Oncología, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil., Lima IPF; Department of Oncology, CRIO Centro Regional Integrado de Oncología, Fortaleza, Brazil., Hughes BGM; Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, QLD, Australia., Pointreau Y; Department of Radiation Oncology, Centre Jean Bernard Institut Inter-régionaL de Cancérologie, Centre de Cancérologie de la Sarthe, Le Mans, France., Aksoy S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Türkiye., Laban S; Head & Neck Cancer Center of the Comprehensive Cancer Center Ulm, Ulm University Medical Center, Ulm, Germany., Greil R; Department of Internal Medicine, Paracelsus Medical University, Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria., Burian M; Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria., Hetnal M; Andrzej Frycz Modrzewski Krakow University, Amethyst Radiotherapy Center, Rydygier Hospital, Krakow, Poland., Delord JP; European Cancer Organisation, Brussels, Belgium., Mesia R; Medical Oncology Department, Catalan Institute of Oncology - Badalona, B-ARGO group, CARE program, IGTP, Badalona, Spain., Taberna M; Savana, Madrid, Spain., Waldron J; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Simon C; Department of Otolaryngology-Head and Neck Surgery, University Medical Center Vaud (CHUV) - Lausanne University Hospital, Lausanne, Switzerland., Gregoire V; Radiation Oncology Department, Léon Bérard Cancer Center, Lyon, France., Harrington K; The Institute of Cancer Research, London, United Kingdom., Black CM; Merck & Co., Inc., Rahway, NJ, United States., Norquist JM; Merck & Co., Inc., Rahway, NJ, United States., Wang A; Merck & Co., Inc., Rahway, NJ, United States., Gumuscu B; Merck & Co., Inc., Rahway, NJ, United States., Bidadi B; Merck & Co., Inc., Rahway, NJ, United States., Siu LL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Source: Frontiers in oncology [Front Oncol] 2025 Oct 06; Vol. 15, pp. 1645509. Date of Electronic Publication: 2025 Oct 06 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41122636
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Machiels+JP%22">Machiels JP</searchLink>; Department of Medical Oncology, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique (Pole MIRO), UCLouvain, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Tao+Y%22">Tao Y</searchLink>; Department of Radiation Oncology, Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Licitra+L%22">Licitra L</searchLink>; Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Burtness+B%22">Burtness B</searchLink>; Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States.<br /><searchLink fieldCode="AU" term="%22Tahara+M%22">Tahara M</searchLink>; Division of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Rischin+D%22">Rischin D</searchLink>; Medical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Alves+GV%22">Alves GV</searchLink>; Medical Oncology, Centro Integrado de Pesquisa em Oncología, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.<br /><searchLink fieldCode="AU" term="%22Lima+IPF%22">Lima IPF</searchLink>; Department of Oncology, CRIO Centro Regional Integrado de Oncología, Fortaleza, Brazil.<br /><searchLink fieldCode="AU" term="%22Hughes+BGM%22">Hughes BGM</searchLink>; Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, QLD, Australia.<br /><searchLink fieldCode="AU" term="%22Pointreau+Y%22">Pointreau Y</searchLink>; Department of Radiation Oncology, Centre Jean Bernard Institut Inter-régionaL de Cancérologie, Centre de Cancérologie de la Sarthe, Le Mans, France.<br /><searchLink fieldCode="AU" term="%22Aksoy+S%22">Aksoy S</searchLink>; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Türkiye.<br /><searchLink fieldCode="AU" term="%22Laban+S%22">Laban S</searchLink>; Head & Neck Cancer Center of the Comprehensive Cancer Center Ulm, Ulm University Medical Center, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Greil+R%22">Greil R</searchLink>; Department of Internal Medicine, Paracelsus Medical University, Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria.<br /><searchLink fieldCode="AU" term="%22Burian+M%22">Burian M</searchLink>; Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria.<br /><searchLink fieldCode="AU" term="%22Hetnal+M%22">Hetnal M</searchLink>; Andrzej Frycz Modrzewski Krakow University, Amethyst Radiotherapy Center, Rydygier Hospital, Krakow, Poland.<br /><searchLink fieldCode="AU" term="%22Delord+JP%22">Delord JP</searchLink>; European Cancer Organisation, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Mesia+R%22">Mesia R</searchLink>; Medical Oncology Department, Catalan Institute of Oncology - Badalona, B-ARGO group, CARE program, IGTP, Badalona, Spain.<br /><searchLink fieldCode="AU" term="%22Taberna+M%22">Taberna M</searchLink>; Savana, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Waldron+J%22">Waldron J</searchLink>; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Simon+C%22">Simon C</searchLink>; Department of Otolaryngology-Head and Neck Surgery, University Medical Center Vaud (CHUV) - Lausanne University Hospital, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Gregoire+V%22">Gregoire V</searchLink>; Radiation Oncology Department, Léon Bérard Cancer Center, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Harrington+K%22">Harrington K</searchLink>; The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Black+CM%22">Black CM</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Norquist+JM%22">Norquist JM</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Wang+A%22">Wang A</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Gumuscu+B%22">Gumuscu B</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Bidadi+B%22">Bidadi B</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Siu+LL%22">Siu LL</searchLink>; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2025 Oct 06; Vol. 15, pp. 1645509. <i>Date of Electronic Publication: </i>2025 Oct 06 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41122636
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2025.1645509
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1645509
    Titles:
      – TitleFull: Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Machiels JP
      – PersonEntity:
          Name:
            NameFull: Tao Y
      – PersonEntity:
          Name:
            NameFull: Licitra L
      – PersonEntity:
          Name:
            NameFull: Burtness B
      – PersonEntity:
          Name:
            NameFull: Tahara M
      – PersonEntity:
          Name:
            NameFull: Rischin D
      – PersonEntity:
          Name:
            NameFull: Alves GV
      – PersonEntity:
          Name:
            NameFull: Lima IPF
      – PersonEntity:
          Name:
            NameFull: Hughes BGM
      – PersonEntity:
          Name:
            NameFull: Pointreau Y
      – PersonEntity:
          Name:
            NameFull: Aksoy S
      – PersonEntity:
          Name:
            NameFull: Laban S
      – PersonEntity:
          Name:
            NameFull: Greil R
      – PersonEntity:
          Name:
            NameFull: Burian M
      – PersonEntity:
          Name:
            NameFull: Hetnal M
      – PersonEntity:
          Name:
            NameFull: Delord JP
      – PersonEntity:
          Name:
            NameFull: Mesia R
      – PersonEntity:
          Name:
            NameFull: Taberna M
      – PersonEntity:
          Name:
            NameFull: Waldron J
      – PersonEntity:
          Name:
            NameFull: Simon C
      – PersonEntity:
          Name:
            NameFull: Gregoire V
      – PersonEntity:
          Name:
            NameFull: Harrington K
      – PersonEntity:
          Name:
            NameFull: Black CM
      – PersonEntity:
          Name:
            NameFull: Norquist JM
      – PersonEntity:
          Name:
            NameFull: Wang A
      – PersonEntity:
          Name:
            NameFull: Gumuscu B
      – PersonEntity:
          Name:
            NameFull: Bidadi B
      – PersonEntity:
          Name:
            NameFull: Siu LL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 10
              Text: 2025 Oct 06
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1